Antiproliferative S-Trityl-l-Cysteine -Derived Compounds as SIRT2 Inhibitors: Repurposing and Solubility Enhancement

Abstract

S-trityl-l-cysteine (STLC) is a well-recognized lead compound known for its anticancer activity owing to its potent inhibitory effect on human mitotic kinesin Eg5. STLC contains two free terminal amino and carboxyl groups that play pivotal roles in binding to the Eg5 pocket. On the other hand, such a zwitterion structure complicates the clinical development of STLC because of the solubility issues. Masking either of these radicals reduces or abolishes STLC activity against Eg5. We recently identified and characterized a new class of nicotinamide adenine dinucleotide-dependent deacetylase isoform 2 of sirtuin protein (SIRT2) inhibitors that can be utilized as cytotoxic agents based on an S-trityl-l-histidine scaffold. Herein, we propose new STLC-derived compounds that possess pronounced SIRT2 inhibition effects. These derivatives contain modified amino and carboxyl groups, which conferred STLC with SIRT2 bioactivity, representing an explicit repurposing approach. Compounds STC4 and STC11 exhibited half maximal inhibitory concentration values of 10.8 ± 1.9 and 9.5 ± 1.2 μM, respectively, against SIRT2. Additionally, introduction of the derivatizations in this study addressed the solubility limitations of free STLC, presumably due to interruption of the zwitterion structure. Therefore, we could obtain drug-like STLC derivatives that work by a new mechanism of action. The new derivatives were designed, synthesized, and their structure was confirmed using different spectroscopic approaches. In vitro and cellular bioassays with various cancer cell lines and in silico molecular docking and solubility calculations of the synthesized compounds demonstrated that they warrant attention for further refinement of their bioactivity.

A novel series of chlorinated plastoquinone analogs: Design, synthesis, and evaluation of anticancer activity

“…The crystal structure of the ABL kinase domain in complex with imatinib was obtained from Protein Data Bank (PDB: 1IEP); ABQ11 was built by ChemDraw Professional 15.1. Before docking simulations, ABQ11 and 1IEP preparation included the addition of hydrogens, the assignment of bond order, and assessment of the correct protonation as previously described (Radwan, Ciftci et al, ; Radwan, Koga et al, ). MOE 2018.01 software (Chemical Computing Group) was employed for preparation, interactive docking, visualization and analysis procedures using its default parameters (Koga et al, ; Tanaka et al, ).…”

NS3 helicase inhibitory potential of the marine sponge Spongia irregularis

“…These co-crystal protein structures represent the most crucial four non-structural HCV protein targets with their native ligands binding within the active site. The QuickPrep module in the MOE soware was used to prepare all the protein structures used in this docking study 28,29 . Using the MOE build suite, 14 dereplicated chemical structures were drawn, and then energyminimized using the MOE default force eld.…”

EGFR-Targeted Pentacyclic Triterpene Analogues for Glioma Therapy

“…The MTT (Dojindo Molecular Technologies, Kumamoto, Japan) assay was carried out using the U251, T98G, U87, Jurkat, and PBMC cells to determine the cytotoxicity of compounds 1-13 and cisplatin as previously described in the literature with small modifications [48,49]. Treated cells were incubated with different concentrations (1-100 µM) of the compounds for 72 h at 37 • C in the CO 2 incubator.…”